Unlocking the Keys to Therapeutic Antibody Development: Analyzing the Core Technologies that Facilitate Immunotherapies

Therapeutic antibodies have revolutionized modern medicine since the first monoclonal antibody was approved by the US Food and Drug Administration (FDA) in 1986. With their high affinity, specificity, low immunogenicity, and ability to target a multitude of biological molecules — this class of drug has become highly sought-after for its therapeutic potential. In fact, nearly 100 FDA-approved treatments employ these unique antibodies!

The therapeutic antibody drug market is rising rapidly, with the global value estimated to exceed $300 billion by 2025. With research and development of a new generation of these antibodies increasingly gaining attention from around the world, many distinct technologies are being employed in their production for varying applications. In just 5 years this field has skyrocketed; already surpassing traditional pharmaceuticals as 2018’s best-selling drugs on an international scale.

Therapeutic Antibody Development | Technologies

  • Hybridoma monoclonal antibody technology provides a powerful tool to identify and isolate specific antibodies. By immunizing mice with an antigen, spleen cells are then fused with myeloma cell lines using polyethylene glycol in order to create hybridomas that produce monoclonal antibodies. This technique also has the ability to harvest these specialized molecules through inoculating tumor cells into mouse abdomens for continued production of targeted immune responses.
  • Phage display technology is a powerful tool for studying antigen-antibody reactions, diagnostics and vaccine development. Using gene recombination techniques, the genes of target proteins are fused with bacteriophage capsid protein to create fusion proteins that coat the phages’ surface. These customized phages can then be used to infect bacteria which in turn allows us to identify antibody specificities while also gathering insight into reaction mechanisms between antigens and antibodies.
  • Single B cell technology is revolutionizing the production of monoclonal antibodies, offering immense genetic diversity and unparalleled efficiency. This emerging technique enables rapid preparation of antigen-specific B cells from animal tissue or blood by amplifying IgG light chain and heavy chain variable region genes via single cell PCR. Single B cell technology has become an essential strategy in quickly developing antibodies against viral infectious diseases, providing a powerful new approach to combat such medical challenges.

Synbio Technologies is revolutionizing the development of antibodies through their innovative platform. With a comprehensive, one-stop service offering including gene sequence integration, de novo design and humanization capabilities alongside recombinant expression services for both monoclonal and polyclonal preparations – our antibody technology promises to make creating custom antigen solutions easier than ever before.

Our dependable, cost-effective solutions support academia, biotech companies and pharmaceutical businesses in their research & development projects for therapeutic antibodies. By leveraging our innovative products and services we strive to facilitate breakthroughs that lead to successful therapies enhanced by synthetically produced components.


When you’re ready to start your next therapeutic antibody breakthrough, you can trust us to help!